Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Date

Click to order products descending

Display 45 Products per page

Disease Analysis: Meningococcal Vaccines
Read More
Meningococcal meningitis is caused by the bacteria Neisseria meningitidis, which causes a serious infection to the lining surrounding the brain and spinal cord. In all, 12 known serogroups of Neisseria meningitidis have been identified, six of which (A, B, C, W, X, and Y) can cause epidemics. The Centers for Disease Control and Prevention (CDC) has reported around 1 in 10 people are asymptomatic carriers of the bacteria.
November 22, 2022
Find out more
Disease Analysis: Diabetic Nephropathy
Read More
Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether.
November 21, 2022
Find out more
Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

$1,318.00

This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 18, 2022
Find out more
Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)
Read More
The diagnosis of non-alcoholic fatty liver disease (NAFLD) requires evidence of hepatic steatosis and the lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is a more advanced form of NAFLD where there is liver inflammation with hepatocyte injury, which can lead to hepatic fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage. Detection of fibrosis is important as it is linked to worse outcomes for patients.
November 18, 2022
Find out more
Market Spotlight: Hypogonadism

$1,318.00

The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
November 18, 2022
Find out more
Market Spotlight: Myelofibrosis (MF)

$1,318.00

Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
November 18, 2022
Find out more
Disease Analysis: Chronic Heart Failure
Read More
Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, or structural disorders of the myocardium or valves.
November 17, 2022
Find out more
Disease Analysis: Anemia in Chronic Kidney Disease
Read More
Anemia in chronic kidney disease (CKD), defined as a reduction in red blood cells (RBCs) or hemoglobin levels, often results from decreased levels of erythropoietin and increased levels of hepcidin. Erythropoietin is primarily produced in the kidneys and increases the production of RBCs by acting on precursor cells. H
November 17, 2022
Find out more
Disease Analysis: NHL: Follicular Lymphoma
Read More
Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL) specifically originating from centrocyte and centroblast B cells and usually beginning in the lymph nodes. The disease is among the most common forms of NHL alongside diffuse large B-cell lymphoma (DLBCL), accounting for approximately 35% of all NHLs.
November 17, 2022
Find out more
Market Spotlight: Glioblastoma (GBM)

$1,318.00

This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 16, 2022
Find out more
Market Spotlight: Idiopathic pulmonary fibrosis (IPF)

$1,318.00

This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 16, 2022
Find out more
Disease Analysis: Gastric Cancer
Read More
Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach. The vast majority (95%) of these cancers are adenocarcinomas, and can be further grouped by anatomic origin. The clearest etiological distinction exists between adenocarcinomas of the gastric cardia (the anterior edge of the stomach surrounding the entry point of the esophagus), and those arising in the other anatomical subsites of the stomach – the fundus, body, pylorus, and the antrum. In most cases, gastric adenocarcinomas will begin in the muscularis mucosae and submucosa, then invading deeper lamina of the gastric wall.
November 16, 2022
Find out more
Disease Analysis: Dengue Vaccines
Read More
Dengue virus is a member of the Flaviviridae family, which are also known for causing other diseases including yellow fever, West Nile virus, and tick-borne encephalitis. There are four serologically distinct dengue viruses (DENV-1, DENV-2, DENV-3, and DENV-4), meaning that recovery from infection provides immunity against a specific serotype, but there is little to no cross-immunity towards other serotypes. As a result, a person can be infected multiple times in their lifetime, with subsequent infections being more likely to be severe due to a phenomenon called antibody-dependent enhancement of disease.
November 14, 2022
Find out more
Disease Analysis: Colorectal Cancer
Read More
Colorectal (or bowel) cancer refers to carcinomas arising in the epithelium of the large intestine at any point between the cecal valve and the anus. CRC typically develops through the proliferation of mucosal epithelial cells of the gastrointestinal (GI) wall, eventually forming a polyp or adenoma. As with many other cancers of the GI tract, the vast majority (>95%) are adenocarcinomas.
November 14, 2022
Find out more
Disease Analysis: Ovarian Cancer
Read More
Ovarian cancer is defined as a group of tumors that originate in the ovaries. Most ovarian cancers are epithelial carcinomas which begin in the tissue surrounding the ovary. Other less common types of ovarian tumors include primary peritoneal, fallopian tube, and malignant germ cell tumors. Ovarian cancer is the fourth most common cancer among women, and is the leading cause of gynecological cancer-related death in women.
November 11, 2022
Find out more
Disease Analysis: Triple-Negative Breast Cancer
Read More
Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.
November 11, 2022
Find out more
Disease Analysis: HR+/HER2- Breast Cancer
Read More
Hormone receptor-positive (HR+) is the most common breast cancer subtype, with approximately 70% of breast cancers presenting with overexpression of estrogen receptors, progesterone receptors, or both (De Placido and Pronzato, 2015). Overexpression of the hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
November 11, 2022
Find out more
Disease Analysis: Multiple Myeloma
Read More
Multiple myeloma (MM) is a hematological malignancy characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. The disease represents approximately 1% of all cancers, and 10% of hematological cancers. The hallmarks of MM are high levels of monoclonal (M-) protein, high levels of clonal plasma cells in the bone marrow, and organ damage.
November 10, 2022
Find out more
Disease Analysis: HER2+ Breast Cancer
Read More
Amplification of the HER2/neu oncogene and related genetic elements on chromosome 17 increases HER2 expression and accelerates tumorigenesis. The natural disease progression meant that, historically, women with breast cancer who overexpressed HER2 were found to have significantly shorter disease-free survival and overall survival compared with women without HER2 amplification; however, the introduction of trastuzumab in 1998 drastically changed patient outcomes, to the point where HER2+ breast cancer patients now have the longest median survival of all breast cancer subtypes. HER2 is overexpressed in approximately 20% of breast cancers.
November 9, 2022
Find out more
Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)
Read More
Lung cancer is generally categorized as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). Of these, NSCLC is the most common type of lung cancer, accounting for roughly 85% of all cases. NSCLC can be further divided into non-squamous and squamous NSCLC histologies. Squamous NSCLC refers to patients with squamous cell carcinoma, whereas non-squamous NSCLC includes patients with adenocarcinoma, large cell carcinoma, and other less common subtypes. Incidence of adenocarcinoma and squamous cell carcinoma varies greatly by both geographic region and gender. In general, adenocarcinoma comprises approximately 30–50% of all lung cancer cases, while squamous cell carcinoma accounts for roughly 25–35%.
November 8, 2022
Find out more
Disease Analysis: Psoriasis
Read More
First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive, systemic therapies will continue to be relegated to more severe psoriasis.
November 7, 2022
Find out more
Market Spotlight: Hodgkin’s Lymphoma

$1,318.00

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
November 7, 2022
Find out more
Disease Analysis: Schizophrenia
Read More
The current dynamics of the antipsychotic market show domination by atypical antipsychotics, mainly oral agents, but there is also increasing uptake of long-acting injectable (LAI) neuroleptics, which will continue. Oral atypical antipsychotics that were historical blockbusters are now facing intense generic erosion. The highest-selling oral antipsychotic is Latuda, one of the newer atypical drugs, but its market exclusivity is only set to last until 2023.
November 7, 2022
Find out more
Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

$1,318.00

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 7, 2022
Find out more
Market Spotlight: Osteoarthritis and Osteoarthritis Pain

$1,318.00

This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 4, 2022
Find out more
Disease Analysis: Pulmonary Hypertension
Read More
Pulmonary hypertension (PH) is a life-threatening and often fatal disease characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to a progressive increase in pulmonary vascular resistance (PVR) and, ultimately, the development of right ventricular (RV) dysfunction. Cornerstone histopathological features of the PH vasculopathy include intimal thickening, concentric hypertrophy, and perivascular fibrosis of distal pulmonary arterioles.
November 4, 2022
Find out more
Market Spotlight: Systemic Lupus Erythematosus (SLE)

$1,318.00

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 3, 2022
Find out more
Market Spotlight: Dry Eye Disease

$1,318.00

This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 3, 2022
Find out more
Disease Analysis: COVID-19 Prevention
Read More
COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of October 2021, there have been 245,373,039 confirmed cases of COVID-19, and 4,979,421 deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus.
November 2, 2022
Find out more
Disease Analysis: Migraine
Read More
Migraine is a common, disabling, and recurring neurological disorder characterized by severe headache co-occurring with nausea, vomiting, and other symptoms, the duration of which can range from hours to days.
November 2, 2022
Find out more
Disease Analysis: Seasonal Influenza Vaccines
Read More
Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates.
November 1, 2022
Find out more
Market Spotlight: Small-Cell Lung Cancer (SCLC)

$1,318.00

This Market Spotlight report covers the Small Cell Lung Cancer (SCLC) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
October 26, 2022
Find out more
Market Spotlight: Opioid-Induced Constipation

$1,318.00

This Market Spotlight report covers the Opioid-Induced Constipation (OIC) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.
October 26, 2022
Find out more
Disease Analysis: Acute Myeloid Leukemia (AML)
Read More
AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow, which may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell. “Acute” means that the leukemia may progress rapidly – AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including the lymph nodes, spleen, central nervous system, and testicles.
October 25, 2022
Find out more
Disease Analysis: Renal Cell Carcinoma (RCC)
Read More
Sutent is set to lose ground due to both newer, more effective treatments and imminent biosimilar erosion. Previously the SOC across many treatment settings, the pivotal trials of several newer therapies, which include checkpoint inhibitors Keytruda, Opdivo, and Bavencio, and the RTK inhibitor Cabometyx, have demonstrated significant clinical benefit over Sutent in the first-line setting. Keytruda and Cabometyx have also demonstrated benefit over Sutent in subsequent-line settings.
October 25, 2022
Find out more
Disease Analysis: Depression
Read More
While it is not uncommon to experience feelings of sadness occasionally, in most people these emotions are usually fleeting and pass after a few days. When this manifests in a depressive disorder, a patient’s symptoms interfere with daily life and normal functioning. Depression is the leading cause of disability globally and can cause a multitude of symptoms, many of which are associated with impairment and, ultimately, decreased productivity
October 21, 2022
Find out more
Market Spotlight: Ischemic Stroke

$1,318.00

This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
October 21, 2022
Find out more
Market Spotlight: Basal Cell Carcinoma

$1,318.00

This Market Spotlight report covers the Basal Cell Carcinoma market, comprising key marketed and pipeline drugs, epidemiology, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
October 21, 2022
Find out more
Disease Analysis: Melanoma
Read More
Melanoma accounts for just 1% of all skin cancer cases, but is responsible for the majority of skin cancer-related deaths. Melanoma occurs when melanocytes – pigment-producing cells of the skin that are intercalated in the basal cell layer – become malignant. Although surgical excision is a potentially curative option for many melanoma patients, the disease can disseminate rapidly. Currently, only 27.3% of patients diagnosed with distant metastatic melanoma survive for five years, compared to about 99.0% of those with localized disease. Although 83% of patients present with localized disease, approximately one quarter to one third of these patients will eventually experience disease recurrence.
October 19, 2022
Find out more
Non-Small Cell Lung Cancer (NSCLC) KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for NSCLC. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include TIGIT inhibitors, monalizumab, oleclumab, Rybrevant, and repotrectinib.
October 18, 2022
Find out more
Disease Analysis: Bladder Cancer
Read More
Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary tract infections.
October 18, 2022
Find out more
Non-Small Cell Lung Cancer (NSCLC) KOL Interview – Germany

$599.00

This interview with a Germany-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for NSCLC. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include TIGIT inhibitors, monalizumab, oleclumab, Rybrevant, and repotrectinib.
October 17, 2022
Find out more
Crohn’s Disease KOL Interview – US, South

$599.00

This discussion with a US-based key opinion leader (KOL) includes in-depth opinions on the approved agents and late-stage pipeline drugs in the Crohn’s disease market. In the discussion, the KOL opines in detail about the latest approved agents in Crohn’s disease, along with the treatment approach in fistulizing Crohn’s disease. The impact of biosimilars and the importance of cost regarding the choice of agents in the treatment of Crohn’s disease are also discussed.
October 14, 2022
Find out more
Disease Analysis: Head and Neck Cancer
Read More
Head and neck cancers (HNCs) are defined as any cancer that begins in cells of the oral cavity, pharynx, nose, sinuses, or salivary glands. These cancers are grouped together due to historical similarities in etiology, disease presentation, and manifestation. The vast majority of these cases (90%), collectively referred to as head and neck squamous cell carcinomas (HNSCCs), appear in squamous epithelial cells lining the mucous membranes of these regions. The exception to this is salivary gland cancer, which can appear in any of the salivary glands’ diverse cell types.
October 13, 2022
Find out more
Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention
Read More
Respiratory syncytial virus (RSV), a member of the Paramyxoviridae family, is an enveloped, non-segmented, single-stranded, negativesense RNA virus. It is a common respiratory virus that is the leading cause of bronchiolitis in infants, and is estimated to be responsible for 22% of all episodes of acute lower respiratory tract infections in young children.
October 13, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *